Repurposing FDA Drug Compounds against Breast Cancer by Targeting EGFR/HER2

Repurposing studies have identified several FDA-approved compounds as potential inhibitors of the intracellular domain of epidermal growth factor receptor 1 (EGFR) and human epidermal receptor 2 (HER2). EGFR and HER2 represent important targets for the design of new drugs against different types of...

Descripción completa

Detalles Bibliográficos
Autores principales: Balbuena-Rebolledo, Irving, Padilla-Martínez, Itzia Irene, Rosales-Hernández, Martha Cecilia, Bello, Martiniano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401258/
https://www.ncbi.nlm.nih.gov/pubmed/34451888
http://dx.doi.org/10.3390/ph14080791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401258/
https://www.ncbi.nlm.nih.gov/pubmed/34451888
http://dx.doi.org/10.3390/ph14080791

Ejemplares similares